Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
- 223 Downloads
The objective was to assess the cost-effectiveness of various DMARDs compared with antimalarials (AM) for rheumatoid arthritis (RA) treatment. The data on disease activity, functional status and societal costs were collected from a 1-year cohort of 152 patients with RA receiving at least one DMARD for ≥ 6 months. Incremental cost effectiveness ratio (ICER) was calculated from the societal costs of DMARD treatment compared with AM per one unit of HAQ improvement. All costs were presented in 2001 US dollars. Mean (SD) societal cost of AM treatment was US$ 2,285 (1,154) per patient per year. MTX + AM was less costly and more effective than AM, as the ICER of this combination would save US$ 834 per 1 U of HAQ improvement. MTX + SSZ, leflunomide, and triple therapy (AM + MTX + SSZ) were more effective than AM with additional costs. RA treatment with non MTX-based DMARDs was not cost-effective.
KeywordsRheumatoid arthritis Cost effectiveness analysis Disease modifying antirheumatic drugs Health assessment questionnaire
This study was supported by Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. The authors would like to thank Ms. Youwanuch Kaewkum for collecting the data; Ms. Sureerat Ngamkiatpaisan for providing the unit cost data of King Chulalongkorn Memorial Hospital; Dr. May M. Boggess, Dr. Somrat Lertmaharit, and Dr. Saowalak Hunnangkul for calculating bootstrap estimates by Stata software.
- 12.Suarez-Almazor ME, Osiri M, Emery P, Ottawa Methods Group (2004) Rheumatoid arthritis. In: Tugwell P, Shea B, Boers M et al (eds) Evidence-based rheumatology. BMJ Publishing Group, London, pp 243–282Google Scholar
- 19.Verhoeven AC, Bibo JC, Boers M et al (1998) Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 37:1102–1109PubMedCrossRefGoogle Scholar
- 26.Heston A, Summers R, Aten B (2002) Penn World Table version 6.1. Center for International Comparisons at the University of Pennsylvania (CICUP). <http://pwt.econ.upenn.edu>Google Scholar
- 30.O’Dell JR, Haire CE, Erikson N et al (1996) Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 23(Suppl 44):72–74Google Scholar
- 31.O’Dell J, Paulsen G, Haire C et al (1998) Combination DMARD therapy with methotrexate-sulfasalazine-hydroxychlo-roquine in rheumatoid arthritis: continued efficacy with minimal toxicity at 5 years (abstract). Arthritis Rheum 41(Suppl 9):S132Google Scholar
- 32.O’Dell JR, Leff R, Paulsen G et al (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164–1170PubMedCrossRefGoogle Scholar